ProShare Advisors LLC Acquires 5,592 Shares of Verve Therapeutics, Inc. (NASDAQ:VERV)

ProShare Advisors LLC increased its stake in shares of Verve Therapeutics, Inc. (NASDAQ:VERV) by 30.4% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 24,016 shares of the company’s stock after acquiring an additional 5,592 shares during the period. ProShare Advisors LLC’s holdings in Verve Therapeutics were worth $135,000 as of its most recent filing with the SEC.

Other institutional investors also recently modified their holdings of the company. BVF Inc. IL increased its stake in Verve Therapeutics by 962.2% in the fourth quarter. BVF Inc. IL now owns 6,904,050 shares of the company’s stock valued at $38,939,000 after acquiring an additional 6,254,050 shares during the period. Schonfeld Strategic Advisors LLC grew its stake in Verve Therapeutics by 57.4% in the fourth quarter. Schonfeld Strategic Advisors LLC now owns 3,789,379 shares of the company’s stock valued at $21,372,000 after acquiring an additional 1,382,176 shares during the period. Jacobs Levy Equity Management Inc. increased its holdings in Verve Therapeutics by 18.5% during the 4th quarter. Jacobs Levy Equity Management Inc. now owns 1,848,071 shares of the company’s stock worth $10,423,000 after purchasing an additional 288,678 shares in the last quarter. Geode Capital Management LLC lifted its position in Verve Therapeutics by 1.6% during the 4th quarter. Geode Capital Management LLC now owns 1,625,780 shares of the company’s stock worth $9,172,000 after buying an additional 25,093 shares in the last quarter. Finally, Northern Trust Corp boosted its position in Verve Therapeutics by 12.7% during the fourth quarter. Northern Trust Corp now owns 650,562 shares of the company’s stock valued at $3,669,000 after purchasing an additional 73,295 shares during the last quarter. Institutional investors own 97.11% of the company’s stock.

Verve Therapeutics Stock Performance

Shares of NASDAQ VERV opened at $4.80 on Tuesday. The stock has a fifty day moving average of $4.47 and a 200-day moving average of $5.74. Verve Therapeutics, Inc. has a fifty-two week low of $2.86 and a fifty-two week high of $9.31. The stock has a market cap of $427.89 million, a PE ratio of -1.95 and a beta of 1.82.

Verve Therapeutics (NASDAQ:VERV) last released its earnings results on Wednesday, May 14th. The company reported ($0.35) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.71) by $0.36. Verve Therapeutics had a negative return on equity of 35.23% and a negative net margin of 807.65%. The company had revenue of $32.98 million during the quarter, compared to the consensus estimate of $7.13 million. On average, sell-side analysts predict that Verve Therapeutics, Inc. will post -2.49 EPS for the current year.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on VERV. Royal Bank of Canada dropped their price target on Verve Therapeutics from $17.00 to $15.00 and set an “outperform” rating on the stock in a research note on Tuesday, March 4th. William Blair reissued an “outperform” rating on shares of Verve Therapeutics in a report on Friday, February 21st. Cantor Fitzgerald raised Verve Therapeutics from a “neutral” rating to an “overweight” rating in a research note on Tuesday, April 15th. Guggenheim increased their price target on Verve Therapeutics from $18.00 to $24.00 and gave the company a “buy” rating in a research note on Tuesday, April 15th. Finally, HC Wainwright lifted their price target on shares of Verve Therapeutics from $15.00 to $25.00 and gave the stock a “buy” rating in a report on Monday, April 14th. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $25.75.

About Verve Therapeutics

Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.